The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015–2025)
Abstract
Y]Pentixather deliver targeted radiotherapy to CXCR4-expressing tissues, with pioneering applications in advanced multiple myeloma and acute myeloid leukemia establishing a compelling safety and efficacy profile. While challenges in target heterogeneity and toxicity persist, the future of CXCR4-targeted theranostics is bright, poised for advancement through combinatorial immunotherapies, alpha-emitting radionuclides, and artificial intelligence-driven patient stratification. This review comprehensively synthesizes a decade of progress, affirming CXCR4-targeted theranostics as a cornerstone of precision medicine that faithfully adheres to the "see what you treat, treat what you see" philosophy.
Fields of Study & Subjects
Chemokine receptors and signaling
Cytokine Signaling Pathways and Interactions
Single-cell and spatial transcriptomics
Publication details
- Journal / source
- Theranostics
- Publisher
- Ivyspring International Publisher
- Volume
- 16
- Issue
- 12
- Pages
- 6576–6599
- Publication date
- 1 May 2026
- Language
- EN